Tonix Pharmaceuticals Welcomes New EVP of Commercial Operations
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has made a significant addition to its leadership team by appointing Thomas (Tom) Englese as the new Executive Vice President of Commercial Operations. With over 20 years of extensive experience in the biopharmaceutical sector, Mr. Englese brings a wealth of knowledge in commercial operations, marketing, and brand management.
Expertise and Vision for Growth
Seth Lederman, M.D., the Chief Executive Officer of Tonix, expressed his excitement regarding the appointment, highlighting Mr. Englese's proven ability to develop and implement successful commercial strategies. This is particularly important as the company gears up for the New Drug Application (NDA) submission for TNX-102 SL, a significant milestone in the treatment of fibromyalgia, which is targeted for October 2024.
A Proven Leader
Prior to joining Tonix, Mr. Englese served as the Chief Commercial Officer at Tris Pharmaceuticals, where he played a crucial role in rebranding and expanding the company’s ADHD business. His previous experience at Aziyo Biologics further illustrates his capability to lead commercial organizations across various therapeutic areas, setting strategic directions that optimize company performance.
Experience at Mallinckrodt
Mr. Englese also boasts an impressive career at Mallinckrodt PLC, where he held several positions, ultimately becoming the Senior Vice President and General Manager of North America Hospital Therapies. His expertise was instrumental in guiding a North American franchise with revenues exceeding $1 billion. His leadership during product launches showcases his ability to drive significant growth.
Exciting Times Ahead for Tonix
The timing of Mr. Englese's appointment is crucial for Tonix Pharmaceuticals. "I am excited to join Tonix at this important point in the Company’s growth," he stated. His dedication to advancing the fibromyalgia program and enhancing Tonix's existing commercial capabilities reflects a proactive approach as the company aims to bring TNX-102 SL, a promising treatment, to market.
Advancing Pain Management Solutions
Tonix Pharmaceuticals is committed to transforming therapies that address public health challenges and improve pain management solutions. The company is focused on developing treatments for central nervous system (CNS) disorders. Its promising drug candidate, TNX-102 SL, has successfully completed two statistically significant Phase 3 studies for managing fibromyalgia and has received Fast Track designation from the FDA.
Diverse Pipeline of Innovative Therapies
In addition to TNX-102 SL, Tonix is advancing other therapies such as TNX-1300 for cocaine intoxication and TNX-1500, which targets organ transplant rejection. The company is continuously expanding its diverse portfolio to address various therapeutic areas, including rare diseases and infectious diseases, exemplified by its development of the mpox vaccine, TNX-801.
Strategic Collaboration with the DoD
In line with its ambitious strategy, Tonix has recently secured a significant contract from the U.S. Department of Defense to develop TNX-4200, a broad-spectrum antiviral agent. This initiative not only enhances Tonix's research capabilities but also solidifies its role as a key player in public health responses, particularly in addressing biological threats to military personnel.
Conclusion
As Tonix Pharmaceuticals navigates the complexities of the biopharmaceutical landscape, the appointment of Thomas Englese is expected to bolster its operational capabilities. The company's dedication to innovative therapies, combined with experienced leadership, presents promising prospects for future growth and success in delivering vital treatments to market.
Frequently Asked Questions
Who is Thomas Englese?
Thomas Englese is the newly appointed Executive Vice President of Commercial Operations at Tonix Pharmaceuticals, bringing over 20 years of experience in the biopharmaceutical industry.
What is TNX-102 SL?
TNX-102 SL is a product candidate targeting fibromyalgia that is set to undergo NDA submission in October 2024, having completed significant Phase 3 studies.
What is Tonix Pharmaceuticals' focus?
Tonix Pharmaceuticals focuses on developing therapies for pain management, central nervous system disorders, and other serious health challenges.
What recent contract did Tonix secure?
Tonix recently secured a contract with the U.S. Department of Defense to develop TNX-4200, a small molecule antiviral targeting infections.
How does Tonix support its product development?
Tonix owns a state-of-the-art infectious disease research facility and collaborates on various projects to enhance its drug development portfolio.
